GVB Biopharma, a 22nd Century Group company, has opened a new, strategically-located distribution facility in the Netherlands to support its growing business in Europe, the Middle East, and Africa (EMEA).
 
The new distribution facility will increase existing and new customer access to GVB’s quality hemp/cannabis products, speed up transaction flow, and optimize cross border tax and customs treatment.
 
Recent increases in GVB’s U.S. manufacturing capacity are complementary to the advent of the company’s Netherlands distribution facility. Additional capacity is in part earmarked to satisfy increasing demand in European markets where margins are higher than in the U.S.
 
“We are excited to expand our business operations in Europe, allowing our customers and partners to access quality products in a more efficient manner,” said James A. Mish, chief executive officer of 22nd Century Group. “With our new Netherlands distribution facility, we can now deliver product to our partners in half the time and better serve our growing customer base with quality distillate and isolates. In Europe, the hemp/cannabis industry is expanding rapidly and is expected to reach €3.2 billion by 2025. Our new facility will allow us to capture more of that market share, scale our operations, and expand our customer base in this region.”